VITR
NASDAQ Stockholm
Bioteknik & Läkemedel
Hälsovård
Finansiella rapporter, intäkter, EBIT, värderingsmått och kvartalsprognoser för Vitrolife
| 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | Q1/26 | Q2/26 | |
|---|---|---|---|---|---|---|---|---|
| Omsättning | 3 609,0 | 842,0 | 871,0 | 835,0 | 892,0 | 3 440,0 | 807,0 | 857,0 |
| EBITDA | 962,0 | 257,0 | 243,0 | 253,0 | 196,0 | 949,0 | 251,0 | 295,0 |
| EBIT | 783,0 | 151,0 | 137,0 | 144,0 | −5 267,0 | −4 835,0 | 149,0 | 197,0 |
| EBIT-% | 21,7 % | 17,9 % | 15,7 % | 17,2 % | −590,5 % | −140,6 % | 18,5 % | 23,0 % |
| Vinst före skatt | 674,0 | 141,0 | 132,0 | 131,0 | −5 290,0 | −4 886,0 | 130,0 | 179,0 |
| Nettoresultat | 514,0 | 100,0 | 100,0 | 102,0 | −5 315,0 | −5 013,0 | 101,0 | 129,0 |